Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,097 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kojima M, et al. BMC Cancer. 2019 May 15;19(1):455. doi: 10.1186/s12885-019-5638-9. BMC Cancer. 2019. PMID: 31092221 Free PMC article.
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Makii C, et al. Among authors: kojima m. Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175. Oncotarget. 2016. PMID: 27659536 Free PMC article.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T. Kukita A, et al. Among authors: kojima m. Biochem Biophys Res Commun. 2019 May 28;513(2):340-346. doi: 10.1016/j.bbrc.2019.03.155. Epub 2019 Apr 4. Biochem Biophys Res Commun. 2019. PMID: 30955858
Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y, Nagasaka K, Oda K, Makii C, Takeuchi M, Oki S, Honjo H, Kojima M, Miyagawa Y, Taguchi A, Tanikawa M, Sone K, Hiraike H, Matsumoto Y, Wada-Hiraike O, Ayabe T, Osuga Y, Fujii T. Kawata Y, et al. Among authors: kojima m. Cancer Sci. 2020 Oct;111(10):3824-3834. doi: 10.1111/cas.14583. Epub 2020 Aug 7. Cancer Sci. 2020. PMID: 32713096 Free PMC article.
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Kawata A, Honjoh H, Kawata Y, Kashiyama T, Sato M, Taguchi A, Miyamoto Y, Tanikawa M, Tsuruga T, Nagasaka K, Wada-Hiraike O, Osuga Y, Fujii T. Kojima M, et al. Oncol Lett. 2020 Nov;20(5):153. doi: 10.3892/ol.2020.12014. Epub 2020 Aug 24. Oncol Lett. 2020. PMID: 32934721 Free PMC article.
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T. Wada M, et al. Among authors: kojima m. Biomolecules. 2020 Dec 16;10(12):1686. doi: 10.3390/biom10121686. Biomolecules. 2020. PMID: 33339442 Free PMC article.
Kaempferol, a natural dietary flavonoid, suppresses 17β-estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer.
Chuwa AH, Sone K, Oda K, Tanikawa M, Kukita A, Kojima M, Oki S, Fukuda T, Takeuchi M, Miyasaka A, Kashiyama T, Ikeda Y, Nagasaka K, Mori-Uchino M, Matsumoto Y, Wada-Hiraike O, Kuramoto H, Kawana K, Osuga Y, Fujii T. Chuwa AH, et al. Among authors: kojima m. Oncol Lett. 2018 Nov;16(5):6195-6201. doi: 10.3892/ol.2018.9340. Epub 2018 Aug 21. Oncol Lett. 2018. PMID: 30333884 Free PMC article.
The structure and function of the ghrelin receptor coding for drug actions.
Shiimura Y, Im D, Tany R, Asada H, Kise R, Kurumiya E, Wakasugi-Masuho H, Yasuda S, Matsui K, Kishikawa JI, Kato T, Murata T, Kojima M, Iwata S, Masuho I. Shiimura Y, et al. Among authors: kojima m. Nat Struct Mol Biol. 2025 Jan 20. doi: 10.1038/s41594-024-01481-6. Online ahead of print. Nat Struct Mol Biol. 2025. PMID: 39833471
2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis - secondary publication.
Harigai M, Kaneko Y, Tanaka E, Hirata S, Kameda H, Kaneko K, Kishimoto M, Kohno M, Kojima M, Kojima T, Morinobu A, Nakajima A, Sugihara T, Fusama M, Yajima N, Yanai R, Kawahito Y. Harigai M, et al. Among authors: kojima m. Mod Rheumatol. 2025 Jan 17:roaf006. doi: 10.1093/mr/roaf006. Online ahead of print. Mod Rheumatol. 2025. PMID: 39820350
3,097 results